Some news to pass along there.

WASHINGTON - The government on Friday began posting a list of prescription drugs under investigation for potential safety problems in an effort to better inform doctors and patients.


The first list is a bare-bones compilation naming 20 medications and the potential issue for each. It provides no indication of how widespread or serious the problems might be, leading some consumer advocates to question its usefulness, and prompting industry worries that skittish patients might stop taking a useful medication if they see it listed.

Food and Drug Administration officials said they are trying to walk a fine line in being more open to the public while avoiding needless scares. Congress, in a drug safety bill passed last year, ordered the agency to post quarterly listings of medications under investigation.

"My message to patients is this: Don't stop taking your medicine," said Dr. Janet Woodcock, who heads the FDA's Center for Drug Evaluation and Research. "If your doctor has prescribed a drug that appears on this list, you should continue taking it unless your doctor advises you differently."

At least five of the drugs on the list had problems that already have been publicized. These included the blood thinner heparin, recalled earlier this year, and immune-suppressing medications being studied for a link to cancer in youngsters.

One emerging concern that previously got little attention involved Tysabri, a newer, widely used multiple sclerosis drug. The FDA said it is investigating a potential link to skin melanoma, a dangerous cancer. Doctors in Boston had reported two cases of melanoma in Tysabri patients in a letter to the New England Journal of Medicine in February. Tysabri suppresses the immune system, and it has also been linked to a rare kind of brain infection that is often fatal. Manufacturer Biogen Idec Inc. said it does not believe there is an increased risk of melanoma.

The FDA said drugs will be placed on the list based on reports it receives from hospitals, doctors and patients.

"What's new here is that we are telling the public really at the earliest stage what we are working on," said Dr. Gerald Dal Pan, head of the FDA's drug safety office. "I think the public told us, 'We want to know what you are working on.' And we are responding to that."

The list is not just a reflection of raw data, but more like what a police officer would call "probable cause." Officials said a drug will only be listed if FDA safety reviewers determine that a reported problem deserves a closer look.

"Our hope is that this list will serve not only as a means of communication to the public, but that it will also serve to encourage (medical) providers to provide us with additional reports should they see similar kinds of adverse events with the drugs that are on the list," said Dr. Paul Seligman, who is responsible for the FDA's safety communications.

Consumer advocates called the listing a positive step, but said it needs to be fleshed out.

"It's a good thing to get started but it needs to have much more detail if it's to have significant safety value," said Thomas J. Moore, a senior scientist with the Institute for Safe Medication Practices. "A table with just a few words of description is quite limited."

"It's just the most basic warning system," said Diana Zuckerman, president of the National Research Center for Women and Families. "It's not going to say how many reports there were. It's not going to say how many died and how many were hospitalized."

Nor is it clear how drugs suspected of a problem will be removed from the list if later exonerated.

The Pharmaceutical Research and Manufacturers of America, the main industry lobbying group, said it supports giving more safety information to doctors and patients, but worries that some will be needlessly alarmed.

"Our reservation is that patients will be abruptly stopping therapy," said Alan Goldhammer, a vice president of the organization. "One can't generalize with an emerging safety notice. It may affect half the patients, a quarter of the patients, or only a small subset of the patients."

___

On the Net:

FDA drug evaluation and research: https://tinyurl.com/5bu2om

Email Story IM Story Printable View Yahoo! Buzz RECOMMEND THIS STORY
Recommend It:

Average (70 votes)
» Recommended Stories
Health News
Gene domino effect behind brain, pancreatic tumors AP FDA orders stronger warnings for 4 arthritis drugs AP Study: Workers to pay more for health care AP Study: New way to spot breast cancer shows promise AP Obesity Worsens Asthma HealthDay Most Viewed - Health
List of medications with potential safety problems AP Study confirms harms of anabolic steroid abuse Reuters FDA orders stronger warnings for 4 arthritis drugs AP Last of Woolly Mammoths Had North American Roots HealthDay Gene domino effect behind brain, pancreatic tumors AP Health Video
Galaxy Of Stars Line Up To Battle Cancer CBS 2 / KCAL 9 Los Angeles - 19 minutes ago Don't Touch This FOX News - 2 hours, 9 minutes ago Teeth Whitening Obsession CNN - Fri Sep 5, 12:16 PM ET Wired to Cheat? FOX News - Fri Sep 5, 12:06 PM ET Health Video Galaxy Of Stars Line Up To Battle Cancer
CBS 2 / KCAL 9 Los Angeles
Don't Touch This
FOX News
» All news video
News Search
Search

Related Searches:

multiple sclerosis drug
Biogen Idec Inc
melanoma
Food and Drug Administration officials
Yahoo! News Topic Pages
In-depth coverage on topics such as cancer and stem cell research. Elsewhere on the Web
ABC News: Persons of the Week: Cancer Survivors
ABC News: 10 Germy Surfaces You Touch Every Day
Time.com: Collider Triggers End-of-World Fears
From Y! Health

Health Questions?
Find answers on Yahoo! Health:


» More from Y! HealthYahoo! Tech

Desktop guide
Compare prices and get the latest how-to advice from Yahoo! Tech.
ADVERTISEMENT

ADVERTISEMENT

Add headlines to your personalized My Yahoo! page
(About My Yahoo! and RSS)
Health - AP
Add to My Yahoo!Medications/Drugs News
Add to My Yahoo! Add to RSS» More news feeds

NEWS ALERTS
Get an alert when there are new stories about:

Diana Zuckerman
multiple sclerosis drug
Biogen Idec Inc
melanoma
Food and Drug Administration officials

» More alerts




--------------------------------------------------------------------------------

Yahoo! - My Yahoo! - Mail
Search: All News Yahoo! News Only News Photos Video/Audio Advanced

Primary Navigation
Home U.S Business World Entertainment Sports Tech Politics Science Health Travel Most Popular Odd News Opinion

Copyright © 2008 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten or redistributed without the prior written authority of The Associated Press.


Copyright © 2008 Yahoo! Inc. All rights reserved.
Questions or Comments
Privacy Policy -Terms of Service - Copyright/IP Policy